Matrix metalloproteinase inhibitors: how can we optimize their development?
Hidalgo
M
M
Eckhardt
S G
SG
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002986:Clinical Trials as Topic; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009930:Organic Chemicals; D010654:Phenylbutyrates
D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; D061965:Matrix Metalloproteinase Inhibitors; D009930:Organic Chemicals; D010654:Phenylbutyrates; C113281:Bay 12-9566